How Pattern Hair Loss Differs Between Men and Women

The useful question with this hair loss staging guide is not whether one photo looks better or worse. It is whether the pattern, timing, measurements, and treatment trade-offs point to a decision that will still make sense six months from now.

A friend of mine, a 31-year-old software developer named Raj, texted me a photo of his scalp last October. He’d angled his phone under the bathroom light at some awkward overhead position, and the picture made his crown look like a clearing in a forest. “How bad is it?” he asked. When I told him a dermatologist would probably call it a Norwood III vertex, he said, “What the hell is a Norwood?” Raj is smart, well-read, spends hours researching laptop specs before buying one. But he’d never encountered the classification system that dermatologists have used to stage male hair loss since 1975. His girlfriend, meanwhile, had been dealing with diffuse thinning along her part line for two years and had already learned she didn’t fit the Norwood system at all. She was a Ludwig Type II.

That gap in how we talk about hair loss between men and women isn’t just semantic. It reflects genuine biological differences in how androgenetic alopecia presents, progresses, and responds to treatment. And the classification systems we use, the Norwood scale for men and the Ludwig/Savin scales for women, exist because the patterns really are that different.

Why the Norwood Scale Has Outlasted Everything Else

James Hamilton published his foundational paper on patterned hair loss in the Annals of the New York Academy of Sciences in 1951. His key observation was elegant and slightly unsettling: men castrated before puberty did not develop the bitemporal recession and crown thinning characteristic of androgenetic alopecia. Androgens were the engine.

O’Tar Norwood took Hamilton’s three-stage framework and, in a 1975 paper in the Southern Medical Journal, expanded it to seven stages with several variant subtypes. The Type A variant, where recession marches straight back from the frontal hairline without the typical island-of-hair-on-the-crown pattern, was one of the additions that made the system actually useful in a clinic room.

Since then, alternatives have been proposed. The BASP (basic and specific) classification arrived in 2007 with the promise of capturing more nuance. It hasn’t displaced Norwood in routine practice, and the reason is boring but important: the Norwood scale is simple enough for two dermatologists to agree on a stage, and detailed enough to guide treatment decisions. That balance is surprisingly hard to achieve. It’s the QWERTY keyboard of hair loss staging. Not theoretically optimal, but functionally dominant because it works well enough and everyone already knows it.

For women, though, Norwood doesn’t apply. Female pattern hair loss (FPHL) typically presents as diffuse thinning centered on the midline part, with preservation of the frontal hairline. The Ludwig scale (three stages of increasing central thinning) and the Savin scale (which adds density-based gradations) are the standard tools. Patients who want a visual reference for both male and female staging can review this hair loss staging guide, which includes photographic examples and clinical context.

See also: The Future of Technology: What to Expect in the Next Decade

The Biology Under the Pattern

The molecule at the center of all this is dihydrotestosterone, or DHT. The enzyme 5-alpha reductase converts circulating testosterone into DHT, which is a more potent androgen. In genetically susceptible follicles (and only in those follicles, which is why the back and sides of the scalp are usually spared), DHT binds to the androgen receptor in the dermal papilla and gradually sabotages the hair cycle.

What happens over successive cycles: the anagen (growth) phase shortens, the telogen (resting) phase lengthens, and the dermal papilla itself physically shrinks. Thick, pigmented terminal hairs become thin, short, colorless vellus hairs. This is follicular miniaturization, and it’s the hallmark finding when a dermatologist examines an affected scalp under trichoscopy.

The genetics are polygenic. Yes, the androgen receptor gene lives on the X chromosome, which is why the “look at your mother’s father” heuristic has some basis. But autosomal loci contribute meaningfully too, meaning your dad’s side matters. Family history is a clue, not a verdict.

In women, the androgen picture is more complicated. FPHL involves androgen sensitivity in many cases, but some women with classic pattern thinning have completely normal androgen levels. The current thinking is that local follicular sensitivity and possibly non-androgenic pathways play a larger role in women than in men. This is part of why finasteride, which works by blocking 5-alpha reductase, has a strong evidence base in men but a weaker and more complicated one in women (and is contraindicated in pregnancy due to teratogenic risk).

What Treatment Actually Looks Like in 2026

The honest framing: treatment works best early, before follicles have fully miniaturized. Once a follicle is gone, no topical or oral medication brings it back. That’s what transplantation is for.

Finasteride 1 mg daily has the deepest evidence base for men. The original five-year randomized trial, published in the Journal of the American Academy of Dermatology (JAAD) in 2002, showed sustained improvements in hair count versus placebo. Sexual side effects affect a small percentage of users in randomized trials and are generally reversible on discontinuation. Generic finasteride costs $10 to $25 per month at US pharmacies with discount cards; branded Propecia runs $70 to $90 with no clinical advantage. That’s one of the more straightforward value calculations in medicine.

Topical minoxidil 5% is FDA-approved over the counter for both sexes. The mechanism isn’t fully understood (potassium channel opening, vasodilation, some direct follicular effect that prolongs anagen). Visible results typically appear at three to six months. Generic costs $10 to $30 monthly. Foam and solution are clinically equivalent, though foam causes less scalp irritation for some people.

Low-dose oral minoxidil (0.25 to 5 mg daily) has gained significant traction since a 2021 multicenter study by Vañó-Galván et al. in JAAD documented its efficacy and safety profile in 1,404 patients. Periorbital edema and body hair growth (hypertrichosis) are the main side effects at low doses. This has become a go-to for patients who can’t tolerate or won’t adhere to twice-daily topical application.

Dutasteride inhibits both type I and type II 5-alpha reductase isoforms, lowers DHT more aggressively than finasteride, and has produced larger hair density improvements in head-to-head trials (Olsen et al., JAAD, 2006). It’s approved for benign prostatic hypertrophy and used off-label for hair loss.

PRP and microneedling have a modest evidence base as adjuncts. Smaller randomized trials in JAMA Dermatology show positive but variable results. They’re reasonable add-ons. They’re not replacements for medical therapy. First-year PRP costs ($500 to $1,500 per session, three to four sessions recommended) can easily exceed an entire year of combination finasteride plus minoxidil.

Hair transplantation (FUE or FUT) is the only option that physically moves follicles from donor to recipient areas. In the US, FUE runs $4 to $10 per graft; a typical 2,500 to 3,500 graft case totals $10,000 to $35,000. Turkish clinics offer $2,000 to $5,000 for comparable graft counts, reflecting labor cost differences rather than necessarily quality differences. (Though quality variation in medical tourism is real, and due diligence matters.)

Insurance generally doesn’t cover any of this. HSAs and FSAs may cover prescribed medications and office visits but typically exclude surgery.

The Lifestyle Factors That Actually Move the Needle

Most lifestyle advice about hair loss is noise. But a few signals are clear in the peer-reviewed literature (primarily JAAD and the International Journal of Trichology):

Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies consistently show higher rates of androgenetic alopecia in smokers versus matched nonsmokers. If you needed another reason to quit, here it is.

Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium mechanisms. Repletion helps. But supplementing when you’re already iron-replete does nothing for hair density.

Severe acute stress can precipitate telogen effluvium starting two to three months after the event, typically resolving within six to nine months. It can also unmask underlying pattern loss that was previously subclinical, which is a particularly cruel combination.

Severe caloric restriction, very low protein intake, and rapid weight loss all reliably trigger telogen effluvium. This has become clinically relevant in the GLP-1 agonist era, where rapid weight loss sometimes brings hair shedding as an unwelcome companion.

Anabolic steroid use accelerates pattern loss in genetically susceptible men through supraphysiologic androgen exposure, and the effects may not fully reverse after discontinuation.

My genuinely opinionated take: the amount of money spent on biotin supplements, scalp serums, and laser caps by people who haven’t tried generic finasteride or minoxidil is staggering and, frankly, a failure of public health communication. The boring, cheap, evidence-based treatments are right there.

When Self-Management Isn’t Enough

Most people with classic, slowly progressive pattern hair loss can start with telehealth or OTC minoxidil and be fine. But some situations need an in-person dermatologist, not an app:

Sudden diffuse shedding within the last six months (likely telogen effluvium, needs workup for the cause). Patchy, smooth, well-circumscribed bald spots (alopecia areata, autoimmune, completely different treatment pathway). Scalp pain, burning, redness, scarring, or scaling (possible scarring alopecia like lichen planopilaris or frontal fibrosing alopecia, where delay means permanent follicle destruction). Hair loss in women with irregular periods, acne, or excess body hair (warrants endocrine evaluation for PCOS or other androgen excess). Loss progressing faster than one Norwood stage per year in a young patient. Or failure to respond after 12 months of documented, consistent medical therapy.

The AAD’s position, which I think is exactly right: any progressive hair loss that concerns the patient is a legitimate reason for a dermatology consultation.

FAQs

Can diet alone slow hair loss?

Diet can address contributing factors like iron deficiency or shedding from severe caloric restriction, but it cannot stop the underlying genetic process of androgenetic alopecia.

Is finasteride safe?

Finasteride is FDA-approved for pattern hair loss at 1 mg daily with a well-characterized safety profile spanning more than two decades. Sexual side effects occur in a small percentage of users in randomized trials and are generally reversible on discontinuation. Discuss risks and benefits with a prescribing clinician.

What is shock loss after a hair transplant?

Shock loss is temporary shedding of native or transplanted hairs in the weeks following transplant surgery. It typically resolves over three to six months as follicles re-enter the growth phase.

Is oral minoxidil better than topical?

Low-dose oral minoxidil produces comparable effects to topical minoxidil with better adherence for many patients. The choice depends on side-effect tolerance and personal preference. It should be made with a prescribing clinician.

Is the Norwood scale used for women?

No. The Norwood scale is designed for male pattern hair loss. Female pattern hair loss is classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.

Should I get a hair transplant if I am in my 20s?

Experienced surgeons approach hair transplantation cautiously in patients in their 20s because the long-term progression pattern isn’t yet established. Medical therapy to stabilize native hair is usually the priority first.

How long before I know if treatment is working?

Most medical therapies for pattern hair loss require a minimum of six months, and ideally 12 months, of consistent use before efficacy can be fairly evaluated. Standardized photographs at consistent intervals are the best way to track change.

References

1. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
2. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
3. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
4. American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
5. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
6. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
7. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
8. Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
9. Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
10. Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.

Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.

Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.